Zacks Research Issues Positive Outlook for Pfizer Earnings

Pfizer Inc. (NYSE:PFE) – Equities researchers at Zacks Research raised their Q3 2025 EPS estimates for Pfizer in a research note issued on Monday, February 24th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings of $0.90 per share for the quarter, up from their prior estimate of $0.83. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.94 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $0.89 EPS, FY2026 earnings at $3.03 EPS and FY2027 earnings at $2.98 EPS.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 EPS.

A number of other research analysts also recently issued reports on PFE. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Price Performance

Pfizer stock opened at $26.76 on Wednesday. The stock’s 50 day moving average is $26.33 and its 200 day moving average is $27.37. Pfizer has a one year low of $24.48 and a one year high of $31.54. The firm has a market cap of $151.62 billion, a P/E ratio of 18.98, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth $28,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.43%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.